Our strategy is to design and optimize the efficacy and safety profiles of RORγ antagonists in prolonged action at the skin while being rapidly eliminated from the systemic circulation, which are suitable for topical therapy in psoriasis. This evidence concerns the gene RORC and psoriasis.